The pharmacogenetics of antiretroviral therapy: a review of studies to date.
Although the ever-expanding armamentarium of antiretroviral drugs has significantly decreased the morbidity and mortality due to human immunodeficiency virus infection, patients and clinicians are increasingly faced with the problems of inadequate or toxic response to therapy that may be genetically mediated. Significant evidence now exists that interindividual differences, such as efficacy of therapy, hypersensitivity reactions, and metabolic complications as a result of antiretroviral therapy, are in part genetically determined. This article reviews the significant studies published to date in the area of the pharmacogenetics of antiretroviral therapy and summarizes current trends, as well as areas where further research is needed.
Quirk
Erin
E
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA. equirk@im.wustl.edu
McLeod
Howard
H
Powderly
William
W
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D016207:Cytokines / Q000378:metabolism; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy*; D006680:HLA Antigens / Q000235:genetics / Q000502:physiology; D006239:Haplotypes; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D010597:Pharmacogenetics; D019707:Receptors, Chemokine / Q000378:metabolism; D000099227:Abacavir
D019380:Anti-HIV Agents; D016207:Cytokines; D015224:Dideoxynucleosides; D006680:HLA Antigens; D019707:Receptors, Chemokine; D000099227:Abacavir